Digitalis: its place in therapy.

Abstract

Since the initial introduction of digitalis 200 years ago by Withering, its low therapeutic ratio has limited the use of this agent. The utility of digitalis in patients with congestive heart failure and a recent myocardial infarction has been questioned recently. Findings of rigorously controlled clinical studies suggest a small but definite hemodynamic and clinical improvement in patients administered digitalis. Congestive heart failure can be effectively treated without cardiac glycosides. However, when used judiciously, digitalis provides an additional agent in our therapeutic armamentarium. The inotropic, dormotropic, and vagomimetic properties are uniquely suited for the patient with supraventricular arrhythmias and compromised left ventricular function.

• Authors: J Somberg, D Keefe, B Levitt
• Journal: Journal of clinical pharmacology (J Clin Pharmacol) Vol. 25 Issue 7 Pg. 555-9 (Oct 1985) ISSN: 0091-2700 [Print] England
• PMID: 3905881 (Publication Type: Journal Article, Review)

Chemical References

• Digitalis Glycosides
• Digoxin

Topics

• Digitalis Glycosides (therapeutic use)
• Digoxin (therapeutic use)
• Heart Failure (drug therapy)
• Humans
• Myocardial Contraction (drug effects)
• Myocardial Infarction (drug therapy)